Page last updated: 2024-08-23

etoposide and tafluposide

etoposide has been researched along with tafluposide in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barret, JM; Etiévant, C; Hill, BT; Imbert, T; Kruczynski, A; Perrin, D; van Hille, B1
Barret, JM; Etiévant, C; Guminski, Y; Hill, BT; Kruczynski, A; Perrin, D; van Hille, B1
Barret, JM; Hill, BT; Olive, PL1
Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A; van Hille, B1
Astruc, J; Barret, JM; Chansard, N; Créancier, L; Duchier, C; Hill, BT; Kruczynski, A; Menon, Y; Van Hille, B1
Bailly, C; Hartley, JA; Irwin, H; Kluza, J; Mazinghien, R1

Other Studies

6 other study(ies) available for etoposide and tafluposide

ArticleYear
F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Biochemical pharmacology, 2000, Apr-01, Volume: 59, Issue:7

    Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Cattle; Cell Nucleus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Enzyme Stability; Etoposide; Evaluation Studies as Topic; Humans; Naphthalenes; Pyrans; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2000
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
    Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:2

    Topics: Aclarubicin; Aminoquinolines; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Etoposide; Humans; Indenes; Indoles; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Pyrans; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms

2000
Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases.
    British journal of cancer, 2000, Volume: 83, Issue:12

    Topics: Animals; Camptothecin; Cell Line; Comet Assay; DNA; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Etoposide; Naphthalenes; Pyrans; Spheroids, Cellular; Time Factors; Topoisomerase I Inhibitors

2000
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
    Anti-cancer drugs, 2000, Volume: 11, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Neoplasm Transplantation; Piperazines; Pyrans; Razoxane; Topoisomerase II Inhibitors; Tumor Cells, Cultured

2000
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Northern; Catalysis; Cell Line, Tumor; Cisplatin; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Leukemia; Mice; Mice, Inbred DBA; Mutation, Missense; Naphthalenes; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Pyrans; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2004
Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide.
    Anti-cancer drugs, 2006, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; DNA, Neoplasm; Etoposide; HL-60 Cells; Humans; Naphthalenes; Pyrans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2006